Effectiveness and safety of <scp>GLP</scp> ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
GLP-1 RAs at submaximal doses induce moderate, yet clinically meaningful weight loss in adults with aHO, with semaglutide showing the highest efficacy. Given the non-negligible risk of hormonal decompensation, specific endocrine monitoring is essential.
Authors
- Hédi Soula (ORCID: https://orcid.org/0000-0001-5306-9712)
- Pauline Faucher (ORCID: https://orcid.org/0000-0001-5472-3851)
- Flora Lambert
- Blandine Gatta‐Cherifi (ORCID: https://orcid.org/0000-0002-7399-1330)
- Christine Poitou (ORCID: https://orcid.org/0000-0001-7769-6331)
- Emilie Guillon
Institutions
- Inserm (FR)
- Sorbonne Université (FR)
- Nutrition et obésité : approches systémiques (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Pitié-Salpêtrière Hospital (FR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1111/dom.70216
- Citations
- 4
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Direction Générale de l’offre de Soins
- Assistance publique-Hôpitaux de Paris